Document is current
Any future updates will be listed below
-
Authors
Mashoudy, Kayla D. https://orcid.org/0000-0001-9577-5092
Brooks, Sarah G.
Andrade, Luis F.
Wagner, Jaxon D.
Yosipovitch, Gil https://orcid.org/0000-0001-6303-1822
- License Information
-
More Information
Article History
Accepted: 22 September 2024
First Online: 17 October 2024
Declarations
:
: None.
: None to declare for Kayla Mashoudy. None to declare for Sarah Brooks. None to declare for Luis Andrade. None to declare for Jaxon Wagner. Conflicts of interest for Dr. Gil Yosipovitch include: Consultant and Board Member for Sanofi, Regeneron, Pfizer, Galderma, Novartis, Eli Lilly, Abbvie, Clexio, Kiniksa, Trevi, Pierre Fabre, LEO, and Escient; Celldex and Bellus; and research support from Pfizer, Sanofi Regeneron, LEO, Eli Lilly, Kiniksa, Novartis, Escient, Bellus, Galderma, and Celldex; and Clexio. Gil Yosipovitch is an Editorial Board member of the American Journal of Clinical Dermatology. Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: Not applicable.
: Not applicable.
: Kayla Mashoudy: conceptualization, methodology, and writing—original and final draft preparation. Sarah Brooks: material preparation and writing—original draft preparation. Luis Andrade: material preparation and writing—original draft preparation. Jaxon Wagner: material preparation and writing—original draft preparation. Gil Yosipovitch: supervision, writing, and manuscript review. All authors read and approved the final manuscript.
: Not applicable.
: Not applicable.
